Schizandrin A supplementation improves nonalcoholic fatty liver disease in mice fed a high-fat and high-cholesterol diet

Nutr Res. 2019 Apr:64:64-71. doi: 10.1016/j.nutres.2019.01.001. Epub 2019 Jan 11.

Abstract

We hypothesized that schizandrin (SCH) A, a lignan found in the fruits of the Schisandra genus, would exert protective effects against high-fat and high-cholesterol (HFHC) diet-induced nonalcoholic fatty liver disease (NAFLD) via regulation of lipid metabolism and oxidative stress. To test our hypothesis, male C57BL/6J mice were fed an HFHC diet with or without SCH A for 15 weeks. There were no significant differences in food intake, body weight, fat mass, and plasma total cholesterol level between the 2 groups. However, supplementation of SCH A significantly decreased levels of plasma free fatty acid and triglyceride, whereas plasma high-density lipoprotein cholesterol level was increased in the SCH A-supplemented mice. Moreover, hepatic free fatty acid, triglyceride, and cholesterol content, as well as hepatic lipid droplet accumulation, were markedly lower in the SCH A group in contrast to the control group. Activity of hepatic enzymes involved in fatty acid and triglyceride synthesis was significantly decreased by SCH A supplementation, whereas SCH A markedly increased hepatic β-oxidation and fatty acid oxidation-related gene expression as well as fecal excretion of free fatty acid and triglyceride. SCH A also significantly increased expression of genes involved in cholesterol homeostasis (biliary cholesterol excretion and cholesterol efflux to high-density lipoprotein) in the liver. Moreover, SCH A significantly decreased hepatic lipid peroxidation, which was accompanied by increased hepatic antioxidant enzymes activity. These results suggest that SCH A could alleviate HFHC diet-induced NAFLD by regulating hepatic lipid metabolism and oxidative stress as well as fecal lipid excretion.

Keywords: Antioxidant activity; High-fat and high-cholesterol diet; Lipid metabolism; Nonalcohol fatty liver disease; Schizandrin A.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Animals
  • Antioxidants / metabolism
  • Cholesterol / blood
  • Cholesterol / metabolism
  • Cholesterol, Dietary / administration & dosage
  • Cholesterol, Dietary / adverse effects
  • Cholesterol, Dietary / blood
  • Cholesterol, Dietary / metabolism*
  • Cholesterol, HDL / blood
  • Cyclooctanes / pharmacology
  • Cyclooctanes / therapeutic use*
  • Diet, High-Fat
  • Dietary Fats / administration & dosage
  • Dietary Fats / adverse effects
  • Dietary Fats / metabolism
  • Dietary Supplements
  • Fatty Acids / metabolism
  • Fatty Acids, Nonesterified / blood
  • Feces / chemistry
  • Lignans / pharmacology
  • Lignans / therapeutic use*
  • Lipid Metabolism / drug effects*
  • Liver / drug effects*
  • Liver / metabolism
  • Male
  • Mice, Inbred C57BL
  • Non-alcoholic Fatty Liver Disease / blood
  • Non-alcoholic Fatty Liver Disease / drug therapy*
  • Non-alcoholic Fatty Liver Disease / etiology
  • Non-alcoholic Fatty Liver Disease / metabolism
  • Oxidative Stress / drug effects*
  • Phytotherapy
  • Plant Extracts / pharmacology
  • Plant Extracts / therapeutic use
  • Polycyclic Compounds / pharmacology
  • Polycyclic Compounds / therapeutic use*
  • Schisandra / chemistry*
  • Triglycerides / blood

Substances

  • Antioxidants
  • Cholesterol, Dietary
  • Cholesterol, HDL
  • Cyclooctanes
  • Dietary Fats
  • Fatty Acids
  • Fatty Acids, Nonesterified
  • Lignans
  • Plant Extracts
  • Polycyclic Compounds
  • Triglycerides
  • schizandrin A
  • Cholesterol